白眉蛇毒血凝酶应用于动脉瘤性蛛网膜下腔出血的临床观察

Clinical observation of hemocoagulase for injection in aneurysmal subarachnoid hemorrhage

目的了解白眉蛇毒血凝酶在动脉瘤性蛛网膜下腔出血中的作用。方法收集2013年1月~2015年12月共421例明确诊断为动脉瘤性蛛网膜下腔出血的病例,分为观察组202例和对照组219例,对照组仅使用氨甲环酸,而观察组联合使用白眉蛇毒血凝酶和氨甲环酸,对比两组在出血率以及新发脑梗死的发生率。结果观察组的再出血率为1.00%,对照组的再出血率为5.48%,差异具有统计学意义(P<0.05);两组的栓塞事件再发生率观察组为6.44%,对照组为8.68%,两组对比无明显统计学差异(P>0.05)。结论联合使用白眉蛇毒血凝酶可以降低动脉瘤性蛛网膜下腔出血的再出血率,且不会增加缺血并发症的发生率。

Objective To understand the role of hemocoagulase in aneurysmal subarachnoid hemorrhage.Methods421cases of diagnosed as aneurismal subarachnoid hemorrhage were collected in our hospital from2013to2015,including219cases in the control group,202cases in the observation group,the control group only used tranexamic acid,and the observe group combined using hemocoagulase and tranexamic acid.Then compared two groups clinical efficacy and complications incidence.Results The observation group rebleeding rate was1.00%,the control group rebleeding rate was5.48%,Contrasts in the two groups was statistically difference(P<0.05),and the rate of embolic events in observation group was6.44%,and the control group was8.68%,The differences between the two groups were non significant(P>0.05).Conclusion The combined use of hemocoagulase and tranexamic acid can reduce the rebleeding rate of aneurysmal subarachnoid hemorrhage and does not increase the incidence of ischemic complications.